The present study supports previous findings that immunotherapy targeting the NLRP3 inflammasome or IL‐1β signaling pathway may reduce the severity and improve the clinical outcomes in MRSA pneumonia secondary to IAV infection.50 This evidence concerns the gene NLRP3 and Methicillin-Resistant Staphylococcus Aureus Pneumonia.